pharmaceutical investing Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
pharmaceutical investing Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
pharmaceutical investing Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
Agios Receives FDA Priority Review for New Drug Application: How are Gene Therapy Drug Approvals Impacting Stocks?
pharmaceutical investing Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
Silver47 and Summa Silver Announce Closing of $6.9 Million Brokered Financing, Including Full Exercise of the Over-Allotment Option
Hempalta Issues Open Call for Strategic Partnerships to Scale Alberta-Based Nature-Based Carbon Program
